Kenvue rises after hitting record low; Trump links autism with Tylenol
Shares of Tylenol maker Kenvue KVUE.N up 5.5% at $17.90 in extended trading after falling 7.5% to a record low of $16.89 earlier in the day
U.S. President Donald Trump says there was a link between the use of popular over-the-counter pain medication Tylenol and the development of autism during pregnancy, a claim which many doctors dispute
The Wall Street Journal reported earlier this month that Health Secretary Robert F. Kennedy Jr. plans to announce that use of KVUE's popular over-the-counter pain medication, Tylenol, by pregnant women is potentially linked to autism, contrary to medical guidelines that say it is safe to use
"We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers," Kenvue says in a statement on Monday
Acetaminophen is the active ingredient in Tylenol
Trump also suggested leucovorin, a form of folic acid, as a treatment for autism symptoms during a White House event
Up to last close, shares were down 20.5% YTD
Related Articles
Fed Rate Cuts: Will the Russell 2000 Outperform the S&P 500?
TradingKey - On 17 September, the Federal Reserve cut interest rates by 25 basis points, marking the official restart of the rate-cutting cycle. In theory, small-cap stocks, compared to large-cap stocks, benefit more from Fed rate cuts. This is because they are more reliant on external financing...
CoreWeave’s Q2 FY2025: AI Surge Drives Record Revenue, but Profit Challenges Persist
TradingKey - CoreWeave, Inc. (NASDAQ: CRWV) Q2 FY2025 earnings delivered strong revenue growth but missed earnings expectations, which led to a roughly 10% stock price drop in after-hours trading. Revenue surged 207% year-over-year, driven by robust demand for its GPU-intensive AI cloud platform.
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.
AppLovin Q2 FY2025 Earnings Review: AI-Fueled Surge Delivers Record Results—So Why Did the Stock Dip After Hours?
TradingKey - AppLovin (NASDAQ: APP) reported strong Q2 FY2025 earnings on August 6, 2025, driven by its AI-powered advertising platform, Axon 2.0, and the completion of its apps business divestiture. The company exceeded market expectations, although cautious guidance, concerns over long-term impact
SMCI Q4 FY2025 Earnings Review: AI-Driven Growth Offset by Margin Pressures and Execution Challenges
TradingKey - Super Micro Computer, Inc. (NASDAQ: SMCI) reported its Q4 FY2025 earnings on August 5, 2025, after market close, delivering growth but missing both revenue and EPS expectations.
